The treatment paradigm for FLT3-mutated AML patients has been transformed by the advent of small molecule tyrosine kinase inhibitors (midostaurin, gilteritinib) for both newly diagnosed and R/R AML [54,62]. Here, FLT3 is linked to acute myeloid leukemia.